A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Double-Strand Break Repair Pathway Deficient Neoplasms
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2019
Price : $35 *
At a glance
- Drugs Niraparib (Primary)
- Indications Cholangiocarcinoma; Mesothelioma; Renal cell carcinoma; Uveal melanoma
- Focus Therapeutic Use
- 08 Mar 2019 Planned number of patients changed from 47 to 57.
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.
- 21 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.